SCHEMBL664345

SCHEMBL664345

C#CCCCCNCCCCC#C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SAT1 P21673 1/20 0.44
CYP1A2 P05177 4/20 0.39
CYP2C19 P33261 4/20 0.39
HSD17B10 Q99714 2/20 0.39
MAPT P10636 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2D6 P10635 1/20 0.39
CA12 O43570 4/20 0.38
CA6 P23280 4/20 0.38
CA7 P43166 4/20 0.38
CA9 Q16790 4/20 0.38
CA14 Q9ULX7 4/20 0.38
CA5B Q9Y2D0 4/20 0.38
CA2 P00918 3/20 0.38
CA4 P22748 3/20 0.38
CA5A P35218 3/20 0.38
ALOX15 P16050 3/20 0.38
MEN1 O00255 3/20 0.38
KMT2A Q03164 3/20 0.38
TSHR P16473 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL663749 0.90 SAT1 (0.46) SAT1CYP1A2CYP2C19HSD17B10MAPT
SCHEMBL1454742 0.87 TSHR (0.48) SAT1CYP1A2CYP2C19HSD17B10MAPT
SCHEMBL998528 0.85 SAT1 (0.50) SAT1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL18758930 0.82 TSHR (0.62) SAT1CYP1A2CYP2C19MEN1KMT2A
SCHEMBL1062616 0.79
SCHEMBL23583260 0.79
SCHEMBL21661818 0.78 PAOX (0.52) SAT1CYP1A2CYP2C19HSD17B10MAPT
SCHEMBL1452768 0.78
SCHEMBL16587965 0.78
SCHEMBL14549062 0.78 CA12 (0.57) SAT1CYP1A2CYP2C19HSD17B10MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 135 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1807436-B1 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES INC (US) 2014-06-18 EP claimed
EP-2359862-B1 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents INTEZYNE TECHNOLOGIES INC (US) 2013-07-24 EP claimed
EP-2502941-A1 Heterobifunctional poly (ethylene glycol) and uses thereof Intezyne Technologies Inc. (US) 2012-09-26 EP claimed
EP-2359862-A1 Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents Intezyne Technologies Inc. (US) 2011-08-24 EP claimed
EP-2348096-A2 Synthesis of hybrid block copolymers and uses thereof Intezyne Technologies Inc. (US) 2011-07-27 EP claimed
EP-2073850-B1 HYBRID BLOCK COPOLYMER MICELLES WITH MIXED STEREOCHEMISTRY FOR ENCAPSULATION OF HYDROPHOBIC AGENTS INTEZYNE TECHNOLOGIES INC (US) 2010-10-27 EP claimed
JP-2010526183-A 2010-07-29 JP claimed
EP-2152320-A2 ENCAPSULATED CONTRAST AGENTS Intezyne Technologies Incorporated (US) 2010-02-17 EP claimed
US-7612153-B2 conjugate polymer drugs; endcapped polyethers; nontoxic, biocompatible, non-immunogenic, soluble in water and other solvents INTEZYNE TECHNOLOGIES, INC. (US) 2009-11-03 US claimed
EP-1907444-B1 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES INC (US) 2009-08-19 EP claimed
WO-2008106657-A2 ENCAPSULATED AMYLOID-BETA PEPTIDES INTEZYNE TECHNOLOGIES, INC. (US) 2008-09-04 WO claimed
EP-1907444-A2 POLYMERIC MICELLES FOR DRUG DELIVERY Intezyne Technologies Incorporated (US) 2008-04-09 EP claimed
EP-1833958-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF Intezyne Technologies Incorporated (US) 2007-09-19 EP claimed
EP-1807436-A2 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF Intezyne Technologies Incorporated (US) 2007-07-18 EP claimed
US-20060240092-A1 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell INTEZYNE TECHNOLOGIES, INC. 2006-10-26 US claimed
WO-2006107903-A2 POLYMERIC MICELLES FOR DRUG DELIVERY INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-10-12 WO claimed
US-20060172914-A1 Synthesis of hybrid block copolymers and uses thereof INTEZYNE TECHNOLOGIES, INC. 2006-08-03 US claimed
WO-2006074202-A2 SYNTHESIS OF HYBRID BLOCK COPOLYMERS AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-07-13 WO claimed
US-20060142506-A1 Heterobifunctional poly(ethylene glycol) and uses thereof INTEZYNE TECHNOLOGIES, INC. 2006-06-29 US claimed
WO-2006047419-A2 HETEROBIFUNCTIONAL POLY(ETHYLENE GLYCOL) AND USES THEREOF INTEZYNE TECHNOLOGIES, INCORPORATED (US) 2006-05-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060142506-A1 Heterobifunctional poly(ethylene glycol) and uses thereof GNE, ALG1, EPHX2 SAT1 4152/4885CYP1A2 2705/4885CYP2C19 2072/4885
US-20060240092-A1 drug loaded micelle of a triblock polymer tert-butylphenylsilylpropene-polyethylene glycol-b-poly(tert-butylaspartic acid-b-polyphenylalanine-copoly( tert-buyltyrosine) has a drug-loaded inner core, a crosslinked outer core, and a hydrophilic shell ABCB1, TERT, ABCB4 SAT1 3035/4885CYP1A2 3218/4885CYP2C19 2248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.